-
Integration of genetic and clinical risk factors improves the risk classification of uveitis in patients with juvenile idiopathic arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-19 Melissa Tordoff, Samantha L. Smith, Saskia Lawson-Tovey, , Andrew D. Dick, Michael W. Beresford, Athimalaipet V. Ramanan, Kimme L Hyrich, Andrew P Morris, Stephen Eyre, Lucy R Wedderburn, John Bowes
Juvenile idiopathic arthritis (JIA)-associated uveitis (JIAU) is a serious JIA comorbidity that can result in vision impairment. This study aimed to identify genetic risk factors, within the major histocompatibility complex , for JIAU and evaluate their contribution for improving risk classification when combined with clinical risk factors.
-
Performance of the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome in a Mexican cohort Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-19 Erik Cimé‐Aké, Gabriela Hernández‐Molina, Amaya Llorente‐Chávez, Eduardo Martín‐Nares
ObjectiveTo assess the performance of the 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) in a Mexican cohort.MethodsWe enrolled patients with primary (PAPS) and secondary APS (SAPS), and a control group of non‐autoimmune thrombophilia. We evaluated the fulfillment of the 2023 AECC and the 2006 Revised Sapporo classification criteria (2006 RSCC), and their performance
-
Gut microbiome and osteoarthritis: insights from the naturally occurring canine model of OA Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-19 Christina Stevens, Samantha Norris, Liubov Arbeeva, Scott Carter, Masataka Enomoto, Amanda E. Nelson, B. Duncan X. Lascelles
ObjectivesThe purpose was to enhance the current knowledge of the relationship between the gut microbiome and osteoarthritis (OA) and associated pain using pet dogs as a clinically relevant translational model.MethodsFecal samples were collected from 93 owned pet dogs. Dogs were designated either clinically healthy or OA‐pain using validated methods. Metagenomic profiling was performed through shotgun
-
Skeletal muscle composition, power, and mitochondrial energetics in older men and women with knee osteoarthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-17 Giovanna Distefano, Stephanie Harrison, John Lynch, Thomas M. Link, Philip A. Kramer, Sofhia V. Ramos, Theresa Mau, Paul M. Coen, Lauren M. Sparks, Bret H. Goodpaster, Peggy M. Cawthon, Jane A. Cauley, Nancy E. Lane
ObjectiveTo investigate the overall and sex‐specific relationship between presence and severity of knee osteoarthritis (KOA) with muscle composition, power, and energetics in older adults.MethodsMales and females (n=655, 76.1±4.9yrs; 57% females) enrolled in the Study of Muscle, Mobility and Aging (SOMMA) completed standing knee radiographs and knee pain assessments. Participants were divided into
-
Single cell RNA and T-cell receptor sequencing reveals substantive similarities between synovial fluid and synovial tissue T-cells in inflammatory arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Lucy E. Durham, Frances C Humby, Nora Ng, Sarah Ryan, Rosamond Nuamah, Kathy Fung, Athul Menon Kallayil, Pawan Dhami, Bruce W. Kirkham, Leonie S. Taams
-
A genome-wide association study suggests new susceptibility loci for primary antiphospholipid syndrome Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Desiré Casares-Marfil, Manuel Martínez-Bueno, Maria Orietta Borghi, Guillermo Pons-Estel, , Guillermo Reales, Yu Zuo, Gerard Espinosa, Timothy Radstake, Lucas L. van den Hoogen, Chris Wallace, Joel Guthridge, Judith A James, Ricard Cervera, Pier Luigi Meroni, Javier Martin, Jason S. Knight, Marta E. Alarcón-Riquelme, Amr H. Sawalha
-
Critical Review and Recommendations for Enhancing the Analysis of Climate Change Impacts on Rheumatic Conditions Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-10 Xiaozhen Zhao, James Cheng‐Chung Wei, Caifeng Li
-
Air Pollution, Genetic Susceptibility, and Risk of Incident Systemic Lupus Erythematosus: A Prospective Cohort Study Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-10 Meiqi Xing, Yudiyang Ma, Feipeng Cui, Dankang Li, Jianing Wang, Linxi Tang, Lei Zheng, Jian Yang, Yaohua Tian
ObjectiveThere are few existing studies that investigate the risk of systemic lupus erythematosus (SLE) associated with long‐term exposure to air pollutants. This study aimed to explore associations between long‐term exposure to air pollutants and incident SLE and further evaluate interactions and joint effects of genetic risk and air pollutants.MethodsA total of 459,815 participants were included
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-09 Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Jonathan H. Chung, Sonye K. Danoff, Michael D. George, Dinesh Khanna, Gordon Guyatt, Reza D. Mirza, Rohit Aggarwal, Aberdeen Allen, Shervin Assassi, Lenore Buckley, Hassan A. Chami, Douglas S. Corwin, Paul F. Dellaripa, Robyn T. Domsic, Tracy J. Doyle, Catherine Marie Falardeau, Tracy M. Frech, Fiona K. Gibbons, Monique Hinchcliff, Cheilonda
ObjectiveWe provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).MethodsWe developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment
-
Weighing the Cardiovascular Risks of Low‐Dose Glucocorticoids in Rheumatoid Arthritis from Real‐World Data Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Tate M. Johnson
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Jonathan H. Chung, Sonye K. Danoff, Michael D. George, Dinesh Khanna, Gordon Guyatt, Reza D. Mirza, Rohit Aggarwal, Aberdeen Allen, Shervin Assassi, Lenore Buckley, Hassan A. Chami, Douglas S. Corwin, Paul F. Dellaripa, Robyn T. Domsic, Tracy J. Doyle, Catherine Marie Falardeau, Tracy M. Frech, Fiona K. Gibbons, Monique Hinchcliff, Cheilonda
ObjectiveWe provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.MethodsWe developed clinically relevant population
-
Mapping and analysis of protein and gene profiles identify the important role of TGF‐β in synovial invasion in pigmented villonodular synovitis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Tao Li, Yan Xiong, Jian Li, Xin Tang, Yutong Zhong, Zhigang Tang, Qiuping Zhang, Yubin Luo
BackgroundPigmented villonodular synovitis (PVNS) is a rare benign proliferative disease affecting the soft tissue lining the synovial joints and tendons. Its etiology is poorly understood, largely limiting the availability of current therapeutic options. Here, we mapped the synovial gene and protein profiles of patients with PVNS, revealed a link between synovial inflammation and invasion, and elucidated
-
Genetically proxied IL-13 inhibition is associated with risk of psoriatic disease: Mendelian randomization study Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-08 Sizheng Steven Zhao, Kimme Hyrich, Zenas Yiu, Anne Barton, John Bowes
-
-
ERG regulates lymphatic vessel specification genes and its deficiency impairs wound healing‐associated lymphangiogenesis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-05 Takashi Yamashita, Ulas Kaplan, Adri Chakraborty, Grace Marden, Sami Gritli, Daniel Roh, Andreea Bujor, Marcin Trojanowski, Giovanni Ligresti, Jeffrey L Browning, Maria Trojanowska
-
Association of autoantibody concentrations and trajectories with lupus nephritis histological features and treatment response Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Joseph Kheir, Susan Macwana, Wade DeJager, Tim Gross, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H Weisman, Laurence S. Magder, , Joel M. Guthridge, Michelle Petri, Jill Buyon, Judith A. James
Autoantibodies are a hallmark of lupus nephritis (LN), but their association with LN classes and treatment response are not adequately known. In this study, we quantified circulating autoantibodies in the Accelerating Medicines Partnership (AMP) LN longitudinal cohort to identify serological biomarkers of LN histological classification and treatment response, and how these biomarkers change over time
-
Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF inhibitor Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Zhaohui Yang, Panfeng Tao, Xu Han, Anna Kozlova, Tingyan He, Egor Volchkov, Zoya Nesterenko, Dmitryi Pershin, Elena Raykina, Timur Fatkhudinov, Anastasia Korobeynikova, Ivona Aksentijevich, Jun Yang, Anna Shcherbina, Qing Zhou, Xiaomin Yu
Autoinflammation and PLCγ2-associated antibody deficiency and immune dysregulation (APLAID) syndrome is an autoinflammatory disease caused by gain-of-function variants in PLCG2. This study investigates the pathogenic mechanism of a novel variant of PLCG2 in a patient with APLAID syndrome.
-
Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Daniel Small
-
ANOTHER NOTCH IN THE BELT OF RHEUMATOID ARTHRITIS Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-07-04 Stephanie R. Zack, Osama Alzoubi, Neha Satoeya, Kunwar P. Singh, Sania Deen, Wes Nijim, Myles J. Lewis, Costantino Pitzalis, Nadera Sweiss, Lionel B. Ivashkiv, Shiva Shahrara
-
Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-27 Laura Ross, Dylan Hansen, Susanna Proudman, Dinesh Khanna, Ariane L. Herrick, Wendy Stevens, , , Murray Baron, Mandana Nikpour
Accurate measurement of disease activity in systemic sclerosis (SSc) remains a significant clinical challenge. The Scleroderma Clinical Trials Consortium (SCTC) convened an Activity Index Working Group (WG) to develop a novel measure of disease activity (SCTC-AI).
-
Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-27 Mariana Correia Marques, Danielle Rubin, Emily G. Shuldiner, Mallika Datta, Elizabeth Schmitz, Gustavo Gutierrez Cruz, Andrew Patt, Elizabeth Bennett, Alexei Grom, Dirk Foell, Marco Gattorno, John Bohnsack, Rae S. M. Yeung, Sampath Prahalad, Elizabeth Mellins, Jordi Anton, Claudio A. Len, Sheila Oliveira, Patricia Woo, Seza Ozen, , Zuoming Deng, Michael J. Ombrello
-
-
-
-
-
Caffeine inhibits both basal and insulin‐activated urate transport Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-27 Asim K. Mandal, Tony R. Merriman, Hyon K. Choi, David B. Mount
ObjectiveCaffeine, an adenosine receptor antagonist, is a potent central nervous system stimulant that also impairs insulin signaling. Recent studies have suggested that coffee consumption lowers serum urate (SU) and protects against gout, by unknown mechanisms. We hypothesized that caffeine lowers serum urate by affecting activity of urate transporters.MethodsWe examined the effect of caffeine and
-
Authors' Reply Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Lindsay N. Helget, Ted R. Mikuls
-
Autologous CD19‐ targeting CAR T cells in refractory juvenile dermatomyositis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Rebecca Nicolai, Pietro Merli, Patricia Moran Alvarez, Claudia Bracaglia, Francesca Del Bufalo, Emiliano Marasco, Ivan Caiello, Giusi Prencipe, Mattia Algeri, Maria G. Cefalo, Marco Becilli, Concetta Quintarelli, Matilde Sinibaldi, Linda Hanssens, Fabrizio De Benedetti, Franco Locatelli
-
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Joan T. Merrill, Yoshiya Tanaka, David D'Cruz, Karina Vila‐Rivera, Daniel Siri, Xiaofeng Zeng, Amit Saxena, Martin Aringer, Kristin M. D'Silva, Ling Cheng, Mohamed‐Eslam F. Mohamed, Lucia Siovitz, Sumit Bhatnagar, Marie‐Claude Gaudreau, Thao T. Doan, Alan Friedman
-
Highlighting the need for consensus: diverse classification strategies in contemporary research on Idiopathic Inflammatory myopathies Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Keeran Shivakumar, Emily Sun, Ocean Ma, Latika Gupta, Jessica Day
-
The Hydroxychloroquine Conundrum: Striking the Right Balance Between Safety and Efficacy in Rheumatology Practice Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Jinoos Yazdany, Stephen Shiboski, Gabriela Schmajuk
-
MEK1/2 and ERK1/2 mediated lung endothelial injury and altered hemostasis promote diffuse alveolar hemorrhage in murine lupus Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Haoyang Zhuang, Shuhong Han, Neil S. Harris, Westley H. Reeves
ObjectiveAbout 3% of lupus patients develop severe diffuse alveolar hemorrhage (DAH) with pulmonary vasculitis. B6 mice with pristane‐induced lupus also develop DAH, but BALB/c mice are resistant. DAH is independent of TLR signaling and other inflammatory pathways. This study examined the role of the mitogen‐activated protein kinase pathway (MEK1/2‐ERK1/2, JNK, p38).MethodsB6 and BALB/c mice were treated
-
Association of Cardiovascular Outcomes with Low‐Dose Glucocorticoid Use in Patients with Rheumatoid Arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-25 Brian W Coburn, Joshua F Baker, Jesse Y Hsu, Qufei Wu, Fenglong Xie, Jeffrey R Curtis, Michael D George
-
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-24 Austin Barry, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis-Karim, Bryant R. England, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, Tony R. Merriman, James R. O'Dell, Ted R. Mikuls
Initiating urate-lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of flare risk during the initiation and escalation of allopurinol and febuxostat, administered as a treat-to-target strategy with optimal anti-inflammatory prophylaxis.
-
Anti‐drug antibody, therapeutic drug monitoring: status update and future directions in spondyloarthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-24 Dae Hyun Yoo
-
A Multiomic Analysis to Identify Drivers of Subclinical Vascular Disease in Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-24 Christopher Oliveira, Yenealem Temesgen-Oyelakin, Mohammad Naqi, Michael Davis, Faiza Naz, Stefania Dell'Orso, Stephen Brooks, Skyler Kuhn, Tom Hill, Xiaobai Li, Nidhi Patel, Philip Parel, Massimo Gadina, Sarthak Gupta, Nehal Mehta, Sarfaraz A. Hasni, Mariana J. Kaplan
Systemic lupus erythematosus (SLE) increases cardiovascular disease (CVD) risk, and this is not explained by traditional risk factors. Characterization of blood immunologic signatures that associate with subclinical CVD and predict its progression has been challenging and may help identify subgroups at risk.
-
Hydroxychloroquine Dose and Hospitalizations for Active Lupus Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-06-03 Jacquelyn Nestor, Hyon Choi, Christian Mancini, Baijun Zhou, Yuqing Zhang, Karen H. Costenbader, April Jorge
We sought to determine the impact of hydroxychloroquine (HCQ) dose on the risk of hospitalizations for systemic lupus erythematosus (SLE).
-
-
-
-
-
Long-Term Follow-Up of Anti-Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-27 Clarissa Q. Pimentel, Ana Cristina Medeiros-Ribeiro, Andrea Y. Shimabuco, Percival D. Sampaio-Barros, Júlio César B. Moraes, Claudia G. Schainberg, Celio Roberto Gonçalves, Elaine P. Leon, Léonard De Vinci K. Kupa, Sandra G. Pasoto, Nádia E. Aikawa, Clovis A. Silva, Eloisa Bonfa, Carla G. S. Saad
The aim of this study was to evaluate the influence of anti-infliximab (IFX) antibodies on three different points of care: response/tolerance to IFX, tapering strategy, and in a subsequent treatment with a second tumor necrosis factor inhibitor (TNFi).
-
Minor Genetic Overlap Among Rheumatoid Arthritis, Myocardial Infarction, and Myocardial Infarction Risk Determinants Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-23 Anton Öberg Sysojev, Lars Alfredsson, Lars Klareskog, , Gilad N. Silberberg, Saedis Saevarsdottir, Leonid Padyukov, Patrik K. E. Magnusson, Johan Askling, Helga Westerlind
-
Two Broad Categories Overlapping With Rheumatoid Arthritis Observed in Synovial Biopsies from Patients With Juvenile Idiopathic Arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-23 Clément Triaille, Gaëlle Tilman, Charlotte A. Baert, Tatiana Sokolova, Axelle Loriot, Adrien Nzeusseu-Toukap, Laurent Meric de Bellefon, Christine Galant, Cécile Boulanger, Joao E. Fonseca, Caroline Bouzin, Patrick Durez, Bernard R. Lauwerys, Nisha Limaye
The objective is to characterize transcriptomic profiles and immune cell composition and distribution in juvenile idiopathic arthritis (JIA) synovial biopsies, assess for associations of these features with clinical parameters, and compare JIA and rheumatoid arthritis (RA) synovial features.
-
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-21 Oliver FitzGerald, Dafna D. Gladman, Philip J. Mease, Christopher Ritchlin, Josef S. Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
-
Antibodies to Malondialdehyde-Acetaldehyde Adduct Are Associated With Prevalent and Incident Rheumatoid Arthritis–Associated Interstitial Lung Disease in US Veterans Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-20 Nozima Aripova, Geoffrey M. Thiele, Michael J. Duryee, Carlos D. Hunter, Yangyuna Yang, Punyasha Roul, Dana P. Ascherman, Scott M. Matson, Gary Kunkel, Grant W. Cannon, Katherine D. Wysham, Gail S. Kerr, Paul A. Monach, Joshua F. Baker, Jill A. Poole, Ted R. Mikuls, Bryant R. England
The objective of this study is to determine the associations of protein-specific anti–malondialdehyde-acetaldehyde (MAA) antibodies with prevalent and incident rheumatoid arthritis–interstitial lung disease (RA-ILD).
-
Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-20 Gabriel Figueroa-Parra, María C. Cuéllar-Gutiérrez, Mariana González-Treviño, Alain Sanchez-Rodriguez, Jaime Flores-Gouyonnet, José A. Meade-Aguilar, Larry J. Prokop, M. Hassan Murad, María Dall'Era, Brad H. Rovin, Frédéric Houssiau, Farah Tamirou, Fernando C. Fervenza, Cynthia S. Crowson, Michael S. Putman, Alí Duarte-García
Our objective was to evaluate the effect of glucocorticoid regimens on renal response, infections, and mortality among patients with lupus nephritis (LN).
-
Unveiling Metabolic Similarities of Entheses in Patients with Psoriasis and Psoriatic Arthritis Using Noninvasive In Vivo Molecular Imaging: Results From a Cross-sectional Exploratory Study Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-15 Filippo Fagni, Koray Tascilar, Rita Noversa de Sousa, Sara Bayat, Lukas Sollfrank, Arnd Kleyer, Michael Sticherling, Adrian P. Regensburger, Ferdinand Knieling, Markus F. Neurath, Georg Schett, Maximilian Waldner, David Simon
We assessed and compared molecular tissue changes at the entheses in patients with psoriasis (PsO) and psoriatic arthritis (PsA) and in healthy controls (HCs) in vivo using multispectral optoacoustic tomography (MSOT) and described their relationship with clinical and ultrasound findings of enthesitis.
-
Integrating Radiomics and Neural Networks for Knee Osteoarthritis Incidence Prediction Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-15 Shengfa Li, Peihua Cao, Jia Li, Tianyu Chen, Ping Luo, Guangfeng Ruan, Yan Zhang, Xiaoshuai Wang, Weiyu Han, Zhaohua Zhu, Qin Dang, Qianyi Wang, Mengdi Zhang, Qiushun Bai, Zhiyi Chai, Hao Yang, Haowei Chen, Mingze Tang, Arafat Akbar, Alexander Tack, David J. Hunter, Changhai Ding
-
American College of Rheumatology White Paper: The Effects of Climate Change on Rheumatic Conditions—An Evolving Landscape and a Path Forward Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-15 Paul F. Dellaripa, Lily H. Sung, Paul A. Bain, Cristina Lanata, Ashira Blazar, Frederick W. Miller, Candace H. Feldman
Increases in global temperatures and extreme weather events associated with climate change have complex yet poorly understood detrimental impacts on human health. We reviewed the current published literature on climate change–related effects and rheumatic conditions.
-
Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-03 Lea Hoisnard, Antoine Meyer, Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian
-
Burton's line and scar hyperpigmentation in a patient with severe lead poisoning and saturnine gout Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-05-02 Gisela Garcia‐Arellano, Maria Fernanda Ortiz‐Nuño, Griselda Serna‐Peña, Juan Pablo Toledo‐Motta, Ana Victoria Vasquez‐Gallegos, Dionicio Angel Galarza‐Delgado, Jesus Alberto Cardenas‐de la Garza
-
Defining Criteria for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-04-29 Silvia Rosina, Ana I. Rebollo-Giménez, Letizia Tarantola, Angela Pistorio, Yulia Vyzhga, Yasser El Miedany, Hala M. Lotfy, Hend Abu-Shady, Mervat Eissa, Naglaa S. Osman, Waleed Hassan, Marwa Y. Mahgoub, Nermeen A. Fouad, Doaa M. Mosa, Yasmin Adel, Sheren E. M. Mohamed, Ahmed R. Radwan, Mohamed H. Abu-Zaid, Samar A. A. Tabra, Radwa H. Shalaby, Samah I. Nasef, Raju Khubchandani, Archana Khan, Naziya
Our objective was to develop and validate cutoff values in the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10) that distinguish the states of inactive disease (ID), minimal disease activity (MDA), moderate disease activity (MoDA), and high disease activity (HDA) in children with systemic juvenile idiopathic arthritis, based on subjective disease state assessment by the treating pediatric
-
-
-
-
-
American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting May 17–18, 2022 Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-04-15 Jonathan Kay, Nikolay P. Nikolov, Michael H. Weisman
The American College of Rheumatology and the US Food and Drug Administration co-sponsored a public meeting in May 2022 about challenges in the clinical development of drugs for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), focusing on innovative clinical trial designs, outcome measures, and data collection methods. Recommendations include early dose-ranging studies and use of active comparators
-
Unique Interplay Between Antinuclear Antibodies and Nuclear Molecules in the Pathogenesis of Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-04-15 David S. Pisetsky
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. The hallmark of SLE is the production of antibodies to components of the cell nucleus (antinuclear antibodies [ANAs]). These antibodies can bind to DNA, RNA, and protein complexes with nucleic acids. Among ANAs, antibodies to DNA (anti-DNA)
-
A GITRL-mTORC1-GM-CSF Positive Loop Promotes Pathogenic Th17 Response in Primary Sjögren Syndrome Arthritis Rheumatol. (IF 11.4) Pub Date : 2024-04-08 Yuzhou Gan, Haotian Zhou, Yixue Guo, Bo Huang, Hongjiang Liu, Ziye Wang, Zijun Li, Xiaozhen Zhao, Huaqun Zhu, Qimao Han, Hua Ye, Jing He, Qingwen Wang, Zhanguo Li, Xiaolin Sun